Our Programs
Pipeline
Pipeline

Overcoming the hurdles
presented by inherited retinal disease

ATSENA THERAPEUTICS’ programs include cutting-edge gene therapies for leading forms of Leber congenital amaurosis and Usher syndrome. Our pipeline of proprietary assets is powered by adeno-associated virus (AAV) technology tailored to overcome the hurdles presented by inherited retinal disease.

Discover Preclinical
Development
Ind-Enabling Phase 1 Phase 2
Undisclosed
USH1B
LCA1
accessibility optionsAccessibility
Text Size
A
A